Cycle Pharmaceuticals Ltd maintains an average payment time of 26 days, which sits comfortably within a standard 30-day window and suggests a generally prompt payment culture. However, the distribution reveals a notable tail, with 27% of payments falling in the 31–60 day band and 3% exceeding 60 days, indicating that while most payments arrive on time, a meaningful portion experience delays. The overall payment profile reflects moderate consistency rather than strong reliability.
The most significant risk signal is the 55% late payment rate, which is disproportionately high relative to the 26-day average and suggests that a large share of invoices miss agreed payment terms, even if they are ultimately settled within 60 days. This discrepancy between average speed and late payment frequency points to irregular cash flow management or inconsistent internal approval processes rather than chronic financial distress. Suppliers should expect unpredictable payment timing on individual invoices despite the broadly acceptable average.
Cycle Pharmaceuticals Ltd presents a moderate payment risk profile: acceptable average payment speed but a high late payment rate of 55% that warrants caution for suppliers operating on tight cash flow requirements. Suppliers should consider implementing shorter agreed payment terms, such as net 15 or net 20, to compensate for the likelihood of delays pushing settlements past the due date. Proactive invoice follow-up practices and clearly defined late payment penalty clauses are recommended risk mitigation measures before extending significant credit terms.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 29 Jul 2025 | 26 | 70% | 27% | 3% | 55% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Our most frequently used payment terms are 30 days from the receipt of the invoice.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
360
Our payment dispute resolution process ensures supplier invoices are reviewed thoroughly. If we identify an issue with an invoice, such as incorrect pricing, quantities, or non-compliance with the agreed terms, we will raise the dispute with the supplier in writing as soon as possible. The supplier is expected to acknowledge the dispute promptly and provide supporting information or a revised invoice if needed. We aim to resolve disputes within a reasonable timeframe. If necessary, unresolved matters may be escalated to senior contacts on both sides.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Cycle Pharmaceuticals Ltd is a private limited company operating within the pharmaceutical sector. The company focuses on the development and supply of pharmaceutical products, working within the highly regulated UK medicines industry.
The company is registered in England and Wales under company number 07933058 and maintains its registered office at The Broers Building, 21 JJ Thomson Avenue, Cambridge, CB3 0FA. Incorporated on 2 February 2012, the business is based in the East of England region and remains an active, trading entity.
Pharmaceutical companies of this type in the UK market typically specialise in the research, development, manufacturing, and distribution of medicinal products. They operate under the strict regulatory framework governed by the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring that all products meet the required standards for safety, quality, and efficacy.
Cambridge, where Cycle Pharmaceuticals Ltd is headquartered, is recognised as one of the UK's foremost life sciences and pharmaceutical clusters, home to a concentration of biomedical research institutions and specialist organisations. The location at The Broers Building, situated within the Cambridge Biomedical Campus area, places the company at the heart of this established scientific community.